X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
JNJ-40411813 (ADX71149) is a selective metabotropic glutamate subtype 2 (mGlu2) receptor positive allosteric modulator (PAM). It is being evaluated for the treatment of focal onset seizures.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: JNJ-40411813
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
This financing will support the lead product, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen, is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 03, 2023
Details:
ADX71149 (JNJ-40411813) is a novel orally active positive allosteric modulator of metabotropic Glutamate 2 receptor (mGlu2R). It is being developed for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Addex Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
JNJ-40411813 (ADX71149) is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM) used for the treatment of epilepsy.
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
The multi-center study (ClinicalTrials.gov Identifier: NCT04836559) will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: JNJ-40411813
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
